Drug Approval | April 30, 2026
Wanbury's Patalganga site clears Korea FDA inspection with zero observations
Patalganga plant received zero observation from USFDA earlier
Patalganga plant received zero observation from USFDA earlier
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Subscribe To Our Newsletter & Stay Updated
